Generic product of fixed dose combination product [Regulatives / Guidelines]

posted by nobody – 2017-05-16 21:17 (2957 d 21:51 ago) – Posting: # 17360
Views: 6,298

"...In this case two pharmacokinetics bridges may need to be built..."

Emphasis on may, I guess ;-)

Would strongly depend on the clinical data available for R(AB), I assume, if you have to go this way.

You could offer some food offerings to the oracle or some thousand bugs for an SA, to get the official answer to your questions. In fact I believe, you need both BE studies of your option 1 to pass plus an explanation for "no drift relevant" in practice, if you have clinical data only for combi of the monopreparations. FDC can be real pain...


Edit: Please don’t shout! [Helmut]

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
66 visitors (0 registered, 66 guests [including 14 identified bots]).
Forum time: 19:09 CEST (Europe/Vienna)

Medical researches can be divided into two sorts:
those who think that meta is better and those
who believe that pooling is fooling.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5